Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01549834 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 434
- Enrollment target
NCT01549834: Completed Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
NCT01549834 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 434 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (226% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01549834, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 434 participants
- Enrollment target
Study Summary
This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
Primary Outcome
An assessment tool which focuses on cognitive function and memory
Interventions
- DRUG placebo
- DRUG ABT-126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 434 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
What the finished NCT01549834 record still lists
NCT01549834 is an interventional study that assigns participants to a tested intervention. The registered 434 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (226% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01549834 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01549834 about?
NCT01549834 is a clinical study titled "Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors". This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
What is the current status of trial NCT01549834?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 434 participants. The study started on 2012-03. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01549834?
The interventions under investigation include: placebo (DRUG), ABT-126 (DRUG).
Who is sponsoring clinical trial NCT01549834?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01549834's enrollment target sits among peer trials
434 90th of 2000 higher than 1,911 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04743245 · 434 participants · NA
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
- NCT06471920 · 434 participants · NA
Improving Health for Patients With Chronic LBP in Rural Communities Through Telerehabilitation
- NCT07094113 · 434 participants · Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- NCT05563220 · 435 participants · Phase 1
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia